CTLA4 and cancer: ICIs, which combine the proteins of programmed cell death protein 1 (PD-1) axis or cytotoxic T lymphocyte-associated protein 4 (CTLA-4), are capable of improving the clinical prognosis of patients with various forms of cancers [1–4].